![GIOTRIF® : The 1st choice in 1st-line](/themes/custom/boehringerone/images/giotrif-1-mb.jpg)
GIOTRIF® :
The 1st choice in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
AE management in focus: Xerosis
Document ID: PC-MY-102813
04/01/2022
Author: Boehringer Ingelheim
123,000
Views
100k 340
RELATED CONTENT
PC-MY-102813
Production date: Jan 2022
Production date: Jan 2022